Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 8Melanoma 6Carcinoma, Non-Small-Cell Lung 5Colorectal Neoplasms 4Carcinoma, Hepatocellular 4Stomach Neoplasms 3Neoplasm Metastasis 3Lymphoma 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Nasopharyngeal Carcinoma 2Liver Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Renal Cell 2Advanced Solid Tumors 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Solid Tumor 1Skin Neoplasms 1Sarcoma 1Primary Condition: Advanced Tumors 1Neuroendocrine Tumors 1Nasopharyngeal Neoplasms 1Mouth Neoplasms 1Lung Neoplasms 1Locoregionally Advanced Laryngo-hypopharyngeal Squamous Cell Cancer 1Kidney Neoplasms 1High-Risk Resectable NSCLC 1Head and Neck Neoplasms 1Esophageal Neoplasms 1

Interventions

toripalimab 1camrelizumab 1Radiotherapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Tumors × toripalimab × Clear all
NCT05061628 2021-09-29

The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor

Shanghai Junshi Bioscience Co., Ltd.

Phase 1 Unknown
176 enrolled

Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡